BPDCN: state of the art
1Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX.
Hematology. American Society of Hematology. Education Program
|December 7, 2024
Summary
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with unique skin and organ involvement. Advances in diagnosis and targeted therapy, like tagraxofusp, offer new hope for patients.
Area of Science:
- Hematology
- Oncology
- Dermatopathology
Background:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is recognized as a distinct hematologic malignancy.
- It presents with characteristic skin lesions, bone marrow/blood involvement, lymph node invasion, and extramedullary organ disease, including the central nervous system (CNS).
- Historically, BPDCN predominantly affected older males, but recent trends show increasing diagnoses in females, pediatric, and adolescent/young adult populations, alongside CNS+ cases.
Purpose of the Study:
- To highlight the evolving understanding and diagnostic landscape of BPDCN.
- To discuss advancements in therapeutic approaches, particularly targeted agents.
- To underscore the progress in research, international collaboration, and diagnostic tools for BPDCN.
Main Methods:
- Review of clinical presentations, diagnostic criteria, and epidemiological trends in BPDCN.
- Analysis of the impact of the CD123-targeted agent tagraxofusp in the frontline setting.
- Examination of progress in molecular characterization and identification of novel therapeutic targets.
Main Results:
- Increased global diagnosis of BPDCN, with recognition of previously underrepresented patient groups.
- Demonstrated improvements in frontline treatment outcomes with tagraxofusp.
- Expansion of therapeutic strategies beyond CD123, including combination therapies and improved stem cell transplantation protocols.
Conclusions:
- BPDCN diagnosis and management have significantly advanced, improving patient outcomes.
- Ongoing research and novel clinical trials offer continued hope for more effective treatments.
- Multidisciplinary collaboration is crucial for advancing BPDCN care worldwide.
Related Concept Videos
01:23Methods of Documentation V: CBE
880
Charting by Exception, or CBE, is a method of documentation used in healthcare, particularly in nursing, that focuses on documenting only significant or abnormal findings rather than recording every detail. This approach aims to streamline the documentation process, improve efficiency, and ensure that healthcare providers can quickly identify deviations from normalcy in patient assessments.
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...
880
01:27Parentral Nutrition: Centeral and Peripheral Parental Nutrition
101
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
101